Merck’s Anti- Covid Pill ‘Molflu’ 5-Day Course To Cost Rs 1,400 In India

NDTV Coronavirus

Coronavirus: Dr Reddy’s Molnupiravir will likely be bought below model title ‘Molflu’.

New Delhi:

Drugmaker Dr Reddy’s Laboratories Ltd will launch its generic model of Merck’s antiviral COVID-19 tablet, molnupiravir, and worth it at 35 rupees per capsule, an organization spokesperson stated on Tuesday.

The general value for a affected person handled with a 5-day course of 40 capsules of the generic drug, to be bought below model title ‘Molflu’, will come as much as 1,400 rupees ($18.77). As compared, the therapy with Merck’s tablet in the US prices $700.

“Molflu is predicted to be obtainable from early subsequent week in pharmacies all through (India) with explicit give attention to states with excessive caseload of COVID-19,” the corporate spokesperson stated.

India final week gave emergency use approval to molnupiravir together with two vaccines, because the nation braces for a doable spike in coronavirus instances because of the quickly spreading Omicron variant.

India reported 37,379 new COVID-19 instances on Tuesday, its highest since early September.

With a view to show India into a producing hub, Merck has entered into licensing agreements with eight home drugmakers, together with Dr Reddy’s, to make and provide generic variations of molnupiravir to over 100 low- and middle- revenue nations.

A complete of 13 corporations in India will make molnupiravir, the nation’s well being minister stated final week.

Governments around the globe have been scrambling to purchase the same however simpler antiviral therapy from Pfizer, whereas Merck’s tablet has confronted some setbacks after disappointing trial knowledge.

(This story has not been edited by NDTV employees and is auto-generated from a syndicated feed.)


Please enter your comment!
Please enter your name here